About the founder
About Dov Gertz Holds an MSc in Bioinformatics and researched novel CRISPR-family genome-editing systems. His work resulted in a U.S.-licensed patent and a peer-reviewed publication co-authored with a Nobel Prize winner.
About Converge
Converge Bio, founded in 2024, is building AI models that help design and improve new medicines, with a current focus on accelerating antibody discovery and development. The company has grown to a team of 51, including 18 PhDs and 13 MScs, combining deep expertise in AI, biology, and drug development. Converge has raised $33M from Bessemer Venture Partners, the Gates Foundation, TLV Partners, and Vintage, and has partnered with more than a dozen pharmaceutical and biotech companies. Multiple molecules designed by Converge are already advancing into later stages of development, demonstrating the potential of its technology to meaningfully shorten and improve the drug discovery process.
Visit company website 
